Breaking news

Giorgos Mazonakis Death Prompts Investigation Into Private Athens Practice

Greek singer Giorgos Mazonakis, one of the country’s best-known performers, died suddenly at 54, prompting an investigation into the circumstances surrounding his final medical treatment.

Mazonakis had reportedly visited a private medical practice in central Athens for scheduled plasmapheresis before suffering cardiac arrest. He was taken to Elpis Hospital, where he was pronounced dead on Sept. 9.

Investigators Examine What Happened

Authorities are investigating what treatment had been planned, whether plasmapheresis had begun, who was responsible and what medical assessment preceded it. They are also checking the practice’s license, equipment and staffing.

Greek media reports say the doctor responsible for Mazonakis’ treatment testified that plasmapheresis had not started when his condition suddenly deteriorated. He had reportedly visited the practice the previous day and appeared weakened, with difficulties in speech.

Investigators are expected to review his medical history, symptoms and test results. Two doctors were released after giving statements Wednesday night, while a forensic examination is expected to establish the cause of death.

Questions Over The Practice’s License

Greek Health Minister Adonis Georgiadis said the facility was licensed as an internal medicine practice, not a clinic, and argued that plasmapheresis was not permitted under that license. He ordered an inspection by the Athens Medical Association.

Association President Giorgos Patoulis said previous inspections had not recorded a plasmapheresis machine at the practice. A new committee is checking the premises, equipment and staffing.

The doctors’ lawyer, however, said the machines had been properly declared and that the practice was operating lawfully. The Central Health Council is expected to review the rules governing specialized procedures in private practices.

What Is Plasmapheresis?

Plasmapheresis separates plasma from blood before returning the blood cells and platelets to the patient, with the removed plasma replaced by a specialized solution.

Doctors Konstantinos Giannakas and Thanos Dimopoulos of the University of Athens said the procedure is used for certain serious blood, neurological and immune-related diseases. It requires prior assessment and continuous monitoring, with possible complications including low blood pressure, low calcium levels, allergic reactions, bleeding and, more rarely, arrhythmias.

A Three-Decade Career

Born in Nikaia, Piraeus, in 1972, Mazonakis was discovered by PolyGram in 1992 and released his debut album the following year. He became a major figure in contemporary Greek laïko, with a strong following in Greece and Cyprus.

His career included performances in Germany, Australia and the United States, as well as Sofia in 2012 and 2023 and Tirana in 2024. He also appeared as a judge on The Voice of Greece.

LVMH Revenue Rises, But China Weakness Continues To Weigh On Luxury Giant

A Softer Quarter Exposes The Limits Of Luxury’s Recovery

LVMH, the world’s largest luxury group and parent of Louis Vuitton, Dior, Celine and Hennessy, reported revenue of €18.5 billion in the three months to the end of September, underscoring both the scale of its business and the pressure building across parts of the luxury market.

The company’s revenue rose 1.2% year on year in the third quarter, following a 0.1% increase in the second quarter and a 5.9% decline in the first. The trajectory points to stabilization, but not yet to a convincing rebound.

Organic Growth Misses Expectations

Organic sales growth, which strips out currency effects and portfolio changes, slowed to 1% in the third quarter from 3% in the previous quarter. That result fell short of market expectations and reinforced concerns that the luxury cycle remains uneven.

For the first nine months of the year, LVMH generated sales of €57.1 billion, with organic growth of 2%.

In its statement, the company highlighted the breadth of its portfolio, saying that diversification continues to provide resilience in an uncertain geopolitical and economic environment. That remains one of LVMH’s defining strengths: when one category weakens, another can help offset the downturn.

China Remains The Key Pressure Point

LVMH said sales performed well in the United States, Europe and Japan, but conditions in China remained less favorable. That matters because the country has long been one of the most important growth engines for global luxury brands.

The fashion and leather goods division, LVMH’s most closely watched unit, saw organic sales fall 5% as weaker demand in China weighed on performance. Deutsche Bank said the decline was steeper than the roughly 2% drop expected by analysts.

The segment had delivered its first organic sales gain in two years in the previous quarter, making the latest retreat a notable setback.

Brand Equity Faces A Test In China

The quarter also highlighted the reputational risks facing global brands in China. Louis Vuitton drew criticism after suing local tea company Molly Tea over logo copying. Although the company won the case, the dispute sparked social media backlash and boycott calls, adding another layer of pressure to an already fragile environment.

For a company built on scarcity, aspiration and brand discipline, perception is an asset as valuable as inventory. In a market as digitally connected as China, that asset can shift quickly.

Mixed Performance Across The Portfolio

Not every division weakened. LVMH’s selective retailing business, which includes Sephora, posted an 8% organic sales increase. Watches and jewellery, along with wines and spirits, both recorded 6% organic gains.

That broad mix is precisely what has historically given LVMH an advantage over rivals: it can absorb softness in one category without relying on a single growth driver.

Analysts See A Longer Recovery Ahead

Deutsche Bank analysts said the results could lead to further cuts in earnings forecasts for the second half of 2026 and 2027. They added that it is difficult to see what could improve investor sentiment in the near term.

Still, the bank framed the weakness as cyclical rather than structural. In its view, recovery is taking longer because Chinese demand remains subdued, but the problem does not appear to reflect a permanent deterioration in the brand franchise. Analysts said ongoing brand initiatives are beginning to show results, though improvements are likely to remain gradual.

Investor Pressure Continues To Mount

LVMH’s share price has fallen nearly 40% since the start of the year. In September, L’Oréal overtook the group as France’s most valuable listed company, a symbolic shift that captures how sharply sentiment has changed.

Shares in LVMH were down more than 1.6% in Paris around 10 a.m. CEST following the release.

The Future Forbes Realty Global Properties
Uol
eCredo
Aretilaw firm

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter